NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
18. Juni 2024 01:00 ET
|
NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
11. Juni 2024 01:00 ET
|
NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing...
Revolutionary Scientists Honored for Advancements in Gene Therapy for Neuromuscular Diseases and RNA Discoveries: King Faisal Prize Laureates in Medicine, Professor Jerry Mendell, and in Science, Professor Howard Chang, Awarded
22. April 2024 15:29 ET
|
King Faisal Foundation
Riyadh, Saudi Arabia, April 22, 2024 (GLOBE NEWSWIRE) -- During the 46th session of King Faisal Prize on April 22, exceptional accomplishments in the fields of gene therapy for neuromuscular...
NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences
01. März 2024 14:00 ET
|
NMD Pharma
NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences ClC-1 is a chloride ion channel specifically expressed...
Distinguished Scientists with Breakthroughs in Gene Therapy for Neuromuscular Diseases, and Revolutionary RNA Discoveries , Announced as King Faisal Prize Laureates in Medicine & Science
10. Januar 2024 12:45 ET
|
King Faisal Foundation
Riyadh, Saudi Arabia, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Professor Jerry Mendell was announced this year’s laureate in King Faisal Prize for Medicine for his groundbreaking contributions to...
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society
03. Oktober 2023 07:00 ET
|
NMD Pharma
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society NMD Pharma will show the first ever...
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society
03. Oktober 2023 01:00 ET
|
NMD Pharma
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society NMD Pharma will show the first ever...
RISE Healthcare Group Expands Free Trial of HAL Wearable Medical Device
01. August 2022 10:19 ET
|
RISE Healthcare Group
SAN DIEGO, California, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Following the successful launch of a free trial program to bring the Hybrid Assistive Limb (HAL) technology to patients in San Diego, RISE...
RISE Healthcare Group Expands Free Trial of HAL Wearable Medical Device
01. August 2022 10:08 ET
|
RISE Healthcare Group
SAN DIEGO, California, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Following the successful launch of a free trial program to bring the Hybrid Assistive Limb (HAL) technology to patients in San Diego, RISE...
Sarepta Therapeutics to Present at Two Upcoming Investor Conferences
27. Februar 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...